<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20180516039682N3</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-12-30</date_registration>
      <primary_sponsor>Zanjan University of Medical Sciences</primary_sponsor>
      <public_title>Effect of Achillea wilhelmsii oral rinse on chemoradiotherapy induced oral mucositis in head and neck cancers</public_title>
      <acronym></acronym>
      <scientific_title>Evaluating the effect of Achillea wilhelmsii oral rinse on chemoradiotherapy induced oral mucositis in head and neck cancer patients</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-01-20</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>36</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/51721</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Simple individual randomization: A person other than the investigator will blindly and randomly select a number from the random number table for each patient (by moving in all four directions up, down, left and right). If the selected number is even, the patient will assign to the control group and if the selected number is odd, the patient will assign to the intervention group, Blinding description: In this study, Achillea wilhelmsii mouthwash and normal saline mouthwash (placebo) will be available to patients in bottles of the same shape, size and dark color. Participants , outcome assessor and data analyzer will be blinded to the type of mouthwash and the patient's group. In this study, the pharmacist, as the person responsible for preparing mouthwash, will not be blinded to the study groups.</study_design>
      <phase>3</phase>
      <hc_freetext>Oral mucositis (Stomatitis).</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: From the first day of cancer treatment, the intervention group will use Achillea wilhelmsii mouthwash. Achillea wilhelmsii mouthwash will be prepared in the pharmacognosy laboratory of the Faculty of Pharmacy of Zanjan University of Medical Sciences. Patients should hold 15 ml of the prescribed mouthwash in their mouth for 3 minutes 4 times a day (after each meal and before bed) and then expel it. Patients will undergo oral examination on days 0, 7, 14, 21, and 28 to evaluate the severity of the mucositis (according to World Health Organization scale). Immediately after occurrence of grade 1 mucositis, in addition to using Achillea wilhelmsii mouthwash, patients will use Magic mouthwash, which is a common treatment for oral mucositis due to cancer treatment. Intervention 2: Control group: From the first day of cancer treatment, the control group will use placebo mouthwash. Normal saline solution produced by Shahid Ghazi Pharmaceutical Company of Tabriz will be used as a placebo. Patients should hold 15 ml of the prescribed mouthwash in their mouth for 3 minutes 4 times a day (after each meal and before bed) and then expel it. Patients will undergo oral examination on days 0, 7, 14, 21, and 28 to evaluate the severity of the mucositis (according to World Health Organization scale). Immediately after occurrence of grade 1 mucositis, in addition to using placebo mouthwash, patients will use Magic mouthwash, which is a common treatment for oral mucositis due to cancer treatment.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no further information.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr. Raheleh Akhavan Rasoolzadeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Faculty of dentistry, Zanjan university of medical sciences, 13th Ave., Mahdavi Blvd., Shahrak Karmandan</address>
        <city>Zanjan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4515613191</zip>
        <telephone>+98 24 3314 8101</telephone>
        <email>R.rasoolzadeh@zums.ac.ir</email>
        <affiliation>Zanjan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr. Raheleh Akhavan Rasoolzadeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Faculty of dentistry, Zanjan university of medical sciences, 13th Ave., Mahdavi Blvd., Shahrak Karmandan</address>
        <city>Zanjan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4515613191</zip>
        <telephone>+98 24 3314 8101</telephone>
        <email>R.rasoolzadeh@zums.ac.ir</email>
        <affiliation>Zanjan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients with full consciousness
Patients older than 18 years and younger than 60 years
Patients with head and neck malignancies
Patients undergoing chemotherapy and radiotherapy</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patients with oral mucositis
Patients with any systemic diseases other than head and neck malignancies
Patients with a history of allergy to Achillea wilhelmsii and medicinal plants
Patients with a history of chemotherapy or radiotherapy
Patients with xerostomia
Use of drugs that reduce salivation
Use of antibiotics, antifungals and systemic anti-inflammatory drugs
Patients with malnutrition
Smoking and alcohol consumption
Use of dentures</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>K12</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Stomatitis and related lesions</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: From the first day of cancer treatment, the intervention group will use Achillea wilhelmsii mouthwash. Achillea wilhelmsii mouthwash will be prepared in the pharmacognosy laboratory of the Faculty of Pharmacy of Zanjan University of Medical Sciences. Patients should hold 15 ml of the prescribed mouthwash in their mouth for 3 minutes 4 times a day (after each meal and before bed) and then expel it. Patients will undergo oral examination on days 0, 7, 14, 21, and 28 to evaluate the severity of the mucositis (according to World Health Organization scale). Immediately after occurrence of grade 1 mucositis, in addition to using Achillea wilhelmsii mouthwash, patients will use Magic mouthwash, which is a common treatment for oral mucositis due to cancer treatment.</i_keyword>
      <i_keyword>Control group: From the first day of cancer treatment, the control group will use placebo mouthwash. Normal saline solution produced by Shahid Ghazi Pharmaceutical Company of Tabriz will be used as a placebo. Patients should hold 15 ml of the prescribed mouthwash in their mouth for 3 minutes 4 times a day (after each meal and before bed) and then expel it. Patients will undergo oral examination on days 0, 7, 14, 21, and 28 to evaluate the severity of the mucositis (according to World Health Organization scale). Immediately after occurrence of grade 1 mucositis, in addition to using placebo mouthwash, patients will use Magic mouthwash, which is a common treatment for oral mucositis due to cancer treatment.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Onset time of oral mucositis. Timepoint: Days 0, 7, 14, 21 and 28 after starting cancer treatment. Method of measurement: Clinical examination by a dentist based on World Health Organization oral mucositis grading scale.</prim_outcome>
      <prim_outcome>Severity of oral mucositis. Timepoint: Days 0, 7, 14, 21 and 28 after starting cancer treatment. Method of measurement: Clinical examination by a dentist based on World Health Organization oral mucositis grading scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Patient's weight. Timepoint: Days 0, 7, 14, 21 and 28 after starting cancer treatment. Method of measurement: Using a digital scale.</sec_outcome>
      <sec_outcome>Severity of oral pain. Timepoint: Days 0, 7, 14, 21 and 28 after starting cancer treatment. Method of measurement: Questionnaire.</sec_outcome>
      <sec_outcome>Satisfaction with mouthwash. Timepoint: Days 0, 7, 14, 21 and 28 after starting cancer treatment. Method of measurement: Questionnaire.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Zanjan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-09-01</approval_date>
        <contact_name>Ethics committee of Zanjan University of Medical Sciences</contact_name>
        <contact_address>Central Station of Zanjan University of Medical Sciences, The Beginning of the Islamic Republic Boulevard, Azadi Square, Zanjan Zanjan Zanjan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
